{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:21:03Z","timestamp":1793038863603,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>It has been proposed that anti-angiogenesis therapy could induce tumor \"vascular normalization\" and further enhance the efficacy of chemotherapy, radiotherapy, target therapy, and immunotherapy for nearly twenty years. However, the detailed molecular mechanism of this phenomenon is still obscure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Overexpression and knockout of CCL28 in human lung adenocarcinoma cell line A549 and murine lung adenocarcinoma cell line LLC, respectively, were utilized to establish mouse models. Single-cell sequencing was performed to analyze the proportion of different cell clusters and metabolic changes in the tumor microenvironment (TME). Immunofluorescence and multiplex immunohistochemistry were conducted in murine tumor tissues and clinical biopsy samples to assess the percentage of pericytes coverage. Primary pericytes were isolated from lung adenocarcinoma tumor tissues using magnetic-activated cell sorting (MACS). These pericytes were then treated with recombinant human CCL28 protein, followed by transwell migration assays and RNA sequencing analysis. Changes in the secretome and metabolome were examined, and verification of retinoic acid metabolism alterations in pericytes was conducted using quantitative real-time PCR, western blotting, and LC\u2013MS technology. Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) was employed to validate the transcriptional regulatory ability and affinity of RXR\u03b1 to specific sites at the ANGPT1 promoter.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our study showed that after undergoing anti-angiogenesis treatment, the tumor exhibited a state of ischemia and hypoxia, leading to an upregulation in the expression of CCL28 in hypoxic lung adenocarcinoma cells by the hypoxia-sensitive transcription factor CEBPB. Increased CCL28 could promote tumor vascular normalization through recruiting and metabolic reprogramming pericytes in the tumor microenvironment. Mechanistically, CCL28 modified the retinoic acid (RA) metabolism and increased ANGPT1 expression via RXR\u03b1 in pericytes, thereby enhancing the stability of endothelial cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We reported the details of the molecular mechanisms of \"vascular normalization\" after anti-angiogenesis therapy for the first time. Our work might provide a prospective molecular marker for guiding the clinical arrangement of combination therapy between anti-angiogenesis treatment and other therapies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-024-03135-3","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T04:01:33Z","timestamp":1722225693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA\/RXRA\/ANGPT1 pathway in lung adenocarcinoma"],"prefix":"10.1186","volume":"43","author":[{"given":"Ying","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guichun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"3135_CR1","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S1470-2045(23)00444-8","volume":"24","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023;24:1206\u201318.","journal-title":"Lancet Oncol"},{"key":"3135_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135:584\u201390.","journal-title":"Chin Med J (Engl)"},{"key":"3135_CR3","doi-asserted-by":"publisher","first-page":"107173","DOI":"10.1016\/j.lungcan.2023.03.009","volume":"179","author":"M Reck","year":"2023","unstructured":"Reck M, Popat S, Groh\u00e9 C, Corral J, Novello S, Gottfried M, et al. Anti-angiogenic agents for NSCLC following first-line immunotherapy: rationale, recent updates, and future perspectives. Lung Cancer. 2023;179:107173.","journal-title":"Lung Cancer."},{"key":"3135_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/0008-5472.CAN-21-3515","volume":"82","author":"HG Augustin","year":"2022","unstructured":"Augustin HG, Koh GY. Antiangiogenesis: vessel regression, vessel normalization, or both? Cancer Res. 2022;82:15\u20137.","journal-title":"Cancer Res"},{"key":"3135_CR5","doi-asserted-by":"crossref","unstructured":"Zhang N, Yin R, Zhou P, Liu X, Fan P, Qian L, et al. DLL1 orchestrates CD8(+) T cells to induce long-term vascular normalization and tumor regression. Proc Natl Acad Sci U S A. 2021;118(22):e2020057118.","DOI":"10.1073\/pnas.2020057118"},{"key":"3135_CR6","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s00432-010-0770-6","volume":"136","author":"G Huang","year":"2010","unstructured":"Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol. 2010;136:1201\u201311.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3135_CR7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s12032-013-0698-1","volume":"30","author":"S Shi","year":"2013","unstructured":"Shi S, Chen L, Huang G. Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature. Med Oncol. 2013;30:698.","journal-title":"Med Oncol"},{"key":"3135_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/apm.12235","volume":"122","author":"S Shi","year":"2014","unstructured":"Shi S, Tao L, Song H, Chen L, Huang G. Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice. APMIS. 2014;122:380\u201391.","journal-title":"APMIS"},{"key":"3135_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s12032-013-0777-3","volume":"31","author":"L Tao","year":"2014","unstructured":"Tao L, Huang G, Shi S, Chen L. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models. Med Oncol. 2014;31:777.","journal-title":"Med Oncol"},{"key":"3135_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58\u201362.","journal-title":"Science"},{"key":"3135_CR11","doi-asserted-by":"publisher","first-page":"e65757","DOI":"10.1371\/journal.pone.0065757","volume":"8","author":"S Shi","year":"2013","unstructured":"Shi S, Wang R, Chen Y, Song H, Chen L, Huang G. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS One. 2013;8:e65757.","journal-title":"PLoS One."},{"key":"3135_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","volume":"20","author":"RR Ramjiawan","year":"2017","unstructured":"Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy? Angiogenesis. 2017;20:185\u2013204.","journal-title":"Angiogenesis"},{"key":"3135_CR13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41593-020-00793-2","volume":"24","author":"DA Hartmann","year":"2021","unstructured":"Hartmann DA, Berthiaume AA, Grant RI, Harrill SA, Koski T, Tieu T, et al. Brain capillary pericytes exert a substantial but slow influence on blood flow. Nat Neurosci. 2021;24:633\u201345.","journal-title":"Nat Neurosci"},{"key":"3135_CR14","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1161\/CIRCULATIONAHA.119.042354","volume":"142","author":"AM Figueiredo","year":"2020","unstructured":"Figueiredo AM, Villacampa P, Dieguez-Hurtado R, Jose Lozano J, Kobialka P, Cortazar AR, et al. Phosphoinositide 3-kinase-regulated pericyte maturation governs vascular remodeling. Circulation. 2020;142:688\u2013704.","journal-title":"Circulation"},{"key":"3135_CR15","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1158\/0008-5472.CAN-19-3533","volume":"80","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Cedervall J, Hamidi A, Herre M, Viitaniemi K, D\u2019Amico G, et al. Platelet-specific PDGFB ablation impairs tumor vessel integrity and promotes metastasis. Cancer Res. 2020;80:3345\u201358.","journal-title":"Cancer Res"},{"key":"3135_CR16","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/ncomms3129","volume":"4","author":"K Hosaka","year":"2013","unstructured":"Hosaka K, Yang Y, Seki T, Nakamura M, Andersson P, Rouhi P, et al. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. Nat Commun. 2013;4:2129.","journal-title":"Nat Commun"},{"key":"3135_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10169","volume":"475","author":"A Facciabene","year":"2011","unstructured":"Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475:226\u201330.","journal-title":"Nature"},{"key":"3135_CR18","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1158\/0008-5472.CAN-19-3074","volume":"80","author":"L Ji","year":"2020","unstructured":"Ji L, Qian W, Gui L, Ji Z, Yin P, Lin GN, et al. Blockade of beta-catenin-induced CCL28 suppresses gastric cancer progression via inhibition of treg cell infiltration. Cancer Res. 2020;80:2004\u201316.","journal-title":"Cancer Res"},{"key":"3135_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/srep27152","volume":"6","author":"G Huang","year":"2016","unstructured":"Huang G, Tao L, Shen S, Chen L. Hypoxia induced CCL28 promotes angiogenesis in lung adenocarcinoma by targeting CCR3 on endothelial cells. Sci Rep. 2016;6:27152.","journal-title":"Sci Rep"},{"key":"3135_CR20","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1172\/JCI125336","volume":"129","author":"J Park","year":"2019","unstructured":"Park J, Zhang X, Lee SK, Song N-Y, Son SH, Kim KR, et al. CCL28-induced RAR\u03b2 expression inhibits oral squamous cell carcinoma bone invasion. J Clin Investig. 2019;129:5381\u201399.","journal-title":"J Clin Investig"},{"key":"3135_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1126\/scitranslmed.aag0945","volume":"10","author":"J Incio","year":"2018","unstructured":"Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, et al. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci Transl Med. 2018;10:10.","journal-title":"Sci Transl Med"},{"key":"3135_CR22","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1158\/1078-0432.CCR-16-3216","volume":"23","author":"T Cascone","year":"2017","unstructured":"Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, et al. The HGF\/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer. Clin Cancer Res. 2017;23:5489\u2013501.","journal-title":"Clin Cancer Res"},{"key":"3135_CR23","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1136\/annrheumdis-2013-204530","volume":"74","author":"Z Chen","year":"2015","unstructured":"Chen Z, Kim SJ, Essani AB, Volin MV, Vila OM, Swedler W, et al. Characterising the expression and function of CCL28 and its corresponding receptor, CCR10, in RA pathogenesis. Ann Rheum Dis. 2015;74:1898\u2013906.","journal-title":"Ann Rheum Dis"},{"key":"3135_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrc2894","volume":"10","author":"H Huang","year":"2010","unstructured":"Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010;10:575\u201385.","journal-title":"Nat Rev Cancer"},{"key":"3135_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16106","volume":"8","author":"M Teichert","year":"2017","unstructured":"Teichert M, Milde L, Holm A, Stanicek L, Gengenbacher N, Savant S, et al. Pericyte-expressed Tie2 controls angiogenesis and vessel maturation. Nat Commun. 2017;8:16106.","journal-title":"Nat Commun"},{"key":"3135_CR26","doi-asserted-by":"publisher","first-page":"e08253","DOI":"10.15252\/emmm.201708253","volume":"13","author":"KA Khan","year":"2021","unstructured":"Khan KA, Wu FT, Cruz-Munoz W, Kerbel RS. Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. EMBO Mol Med. 2021;13:e08253.","journal-title":"EMBO Mol Med."},{"key":"3135_CR27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27:1345\u201356.","journal-title":"Nat Med"},{"key":"3135_CR28","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc2403","volume":"8","author":"LM Ellis","year":"2008","unstructured":"Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579\u201391.","journal-title":"Nat Rev Cancer"},{"key":"3135_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ijms22094871","volume":"22","author":"M Geindreau","year":"2021","unstructured":"Geindreau M, Ghiringhelli F, Bruchard M. Vascular endothelial growth factor, a key modulator of the anti-tumor immune response. Int J Mol Sci. 2021;22:22.","journal-title":"Int J Mol Sci"},{"key":"3135_CR30","doi-asserted-by":"publisher","first-page":"719836","DOI":"10.3389\/fonc.2021.719836","volume":"11","author":"T Yang","year":"2021","unstructured":"Yang T, Xiao H, Liu X, Wang Z, Zhang Q, Wei N, et al. Vascular normalization: a new window opened for cancer therapies. Front Oncol. 2021;11:719836.","journal-title":"Front Oncol"},{"key":"3135_CR31","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1158\/0008-5472.CAN-11-1704","volume":"71","author":"J-L Li","year":"2011","unstructured":"Li J-L, Sainson RCA, Oon CE, Turley H, Leek R, Sheldon H, et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Can Res. 2011;71:6073\u201383.","journal-title":"Can Res"},{"key":"3135_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"3135_CR33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00424-005-1413-7","volume":"450","author":"EP Cummins","year":"2005","unstructured":"Cummins EP, Taylor CT. Hypoxia-responsive transcription factors. Pflugers Arch. 2005;450:363\u201371.","journal-title":"Pflugers Arch"},{"key":"3135_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.intimp.2017.08.012","volume":"51","author":"T Mohan","year":"2017","unstructured":"Mohan T, Deng L, Wang B-Z. CCL28 chemokine: an anchoring point bridging innate and adaptive immunity. Int Immunopharmacol. 2017;51:165\u201370.","journal-title":"Int Immunopharmacol"},{"key":"3135_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2022.12.003","volume":"56","author":"X Zhang","year":"2023","unstructured":"Zhang X, Ji L, Li MO. Control of tumor-associated macrophage responses by nutrient acquisition and metabolism. Immunity. 2023;56:14\u201331.","journal-title":"Immunity"},{"key":"3135_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-023-01860-5","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22:159.","journal-title":"Mol Cancer"},{"key":"3135_CR37","doi-asserted-by":"publisher","first-page":"188762","DOI":"10.1016\/j.bbcan.2022.188762","volume":"1877","author":"H Que","year":"2022","unstructured":"Que H, Fu Q, Lan T, Tian X, Wei X. Tumor-associated neutrophils and neutrophil-targeted cancer therapies. Biochim Biophys Acta Rev Cancer. 2022;1877:188762.","journal-title":"Biochim Biophys Acta Rev Cancer."},{"key":"3135_CR38","doi-asserted-by":"publisher","first-page":"e1484980","DOI":"10.1080\/2162402X.2018.1484980","volume":"7","author":"G Stoll","year":"2018","unstructured":"Stoll G, Pol J, Soumelis V, Zitvogel L, Kroemer G. Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts. Oncoimmunology. 2018;7:e1484980.","journal-title":"Oncoimmunology."},{"key":"3135_CR39","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41423-023-01032-x","volume":"20","author":"H Xu","year":"2023","unstructured":"Xu H, Lin S, Zhou Z, Li D, Zhang X, Yu M, et al. New genetic and epigenetic insights into the chemokine system: the latest discoveries aiding progression toward precision medicine. Cell Mol Immunol. 2023;20:739\u201376.","journal-title":"Cell Mol Immunol"},{"key":"3135_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.molmed.2023.09.003","volume":"30","author":"G Lazennec","year":"2024","unstructured":"Lazennec G, Rajarathnam K, Richmond A. CXCR2 chemokine receptor - a master regulator in cancer and physiology. Trends Mol Med. 2024;30:37\u201355.","journal-title":"Trends Mol Med"},{"key":"3135_CR41","doi-asserted-by":"publisher","first-page":"14868","DOI":"10.1074\/jbc.M114.552257","volume":"289","author":"MK Adams","year":"2014","unstructured":"Adams MK, Belyaeva OV, Wu L, Kedishvili NY. The retinaldehyde reductase activity of DHRS3 is reciprocally activated by retinol dehydrogenase 10 to control retinoid homeostasis. J Biol Chem. 2014;289:14868\u201380.","journal-title":"J Biol Chem"},{"key":"3135_CR42","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1242\/dev.167502","volume":"146","author":"NB Ghyselinck","year":"2019","unstructured":"Ghyselinck NB, Duester G. Retinoic acid signaling pathways. Development. 2019;146:146.","journal-title":"Development"},{"key":"3135_CR43","doi-asserted-by":"publisher","first-page":"108481","DOI":"10.1016\/j.pharmthera.2023.108481","volume":"248","author":"KM DiKun","year":"2023","unstructured":"DiKun KM, Gudas LJ. Vitamin A and retinoid signaling in the kidneys. Pharmacol Ther. 2023;248:108481.","journal-title":"Pharmacol Ther."}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03135-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-03135-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-03135-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T16:06:31Z","timestamp":1722269191000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-03135-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3135"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-03135-3","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"21 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were carried out following the institutional guidelines and approved by the Ethical Review Committee of Comparative Medicine, Jinling Hospital, Nanjing, China. Written informed consent was obtained from all patients before collecting the samples. All the methods were carried out following the institutional guidelines and approved by the Ethical Review Committee of Jinling Hospital, Nanjing, China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have consented for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}